Furthermore, in animal models of lung cancer, gastric cancer, or ovarian cancer, anti-C5a treatment or C5aR1 knockdown, silencing or inhibition decreased proliferation, tumour vascularisation, tumour growth, and metastatic burden [44, 49, 53, 54]. This evidence concerns the gene C5AR1 and gastric cancer.